CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 7 of 7

Some of the metrics are blocked by your
consent settings
Can Frontal Assessment Battery Discriminate between Patients with Alzheimer’s and Frontotemporal Dementia?
(Oxford University Press (OUP), 2025-08-29)
Fabrissio Grandi
;
Loreto Olavarría
;
Mario A Parra
;
David Martínez-Pernía
;
Cesar Serey
Objectives: The Frontal Assessment Battery (FAB) is a widely used tool for assessing executive function. However, its ability to distinguish between Alzheimer's disease dementia (ADD) and behavioural variant frontotemporal dementia (bvFTD) remains under debate. This study assessed the diagnostic utility of the Chilean version of the FAB (FAB-Ch) in differentiating ADD from bvFTD and used data-driven cluster analysis to explore dysexecutive profiles. Method: A total of 288 participants were recruited: 45 with ADD, 33 with bvFTD, and 208 cognitively unimpaired controls (CU). Mean FAB-Ch total scores were compared across groups. Receiver operating characteristic (ROC) curves evaluated the instrument's ability to distinguish (i) dementia from no dementia, (ii) ADD from bvFTD, and (iii) executive dysfunction. Hierarchical cluster analysis was conducted to identify executive profiles among dementia patients. Results: FAB-Ch scores were significantly lower in individuals with dementia compared to controls (p < .001). However, there were no significant differences between ADD and bvFTD groups (p = .59). The FAB-Ch showed strong discriminatory power between dementia and controls (AUC = 0.882; sensitivity = 0.731; specificity = 0.885), but poor discrimination between ADD and bvFTD (AUC = 0.465; p = .59). Cluster analysis among patients with dementia revealed three distinct executive profiles corresponding to different levels of cognitive impairment (p < .001). Conclusion: The FAB-Ch effectively differentiates individuals with dementia from cognitively unimpaired controls but does not distinguish between ADD and bvFTD. Nevertheless, it is sensitive to executive dysfunction and can aid in the clinical characterization of dementia severity and heterogeneity.
1
Some of the metrics are blocked by your
consent settings
Introduction to a Theoretical Model Based on Embodied Cognition: A Pilot Study of the Diagnosis and Treatment of Hemiphobia
(2011)
David Martínez-Pernía
;
CERIC GARRIDO, FRANCISCO JOSE
Scopus© Citations 6 5
Some of the metrics are blocked by your
consent settings
The limitations and challenges in the assessment of executive dysfunction associated with real-world functioning: The opportunity of serious games
(2023)
David Martínez-Pernía
;
Loreto Olavarría
;
Baltasar Fernández-Manjón
;
Victoria Cabello
;
HENRIQUEZ, FERNANDO
Scopus© Citations 5 2
Some of the metrics are blocked by your
consent settings
Standardization and diagnostic utility of the Frontal Assessment Battery for healthy people and patients with dementia in the Chilean population
(2022)
Fabrissio Grandi
;
David Martínez-Pernía
;
Mario Parra
;
Loreto Olavarria
;
David Huepe
<jats:p>ABSTRACT. The Frontal Assessment Battery (FAB) is a screening test that measures executive functions. Although this instrument has been validated in several countries, its diagnostic utility in a Chilean population has not been studied yet. Objectives: This study aimed to (1) adapt FAB in a Chilean population; (2) study the psychometric properties of the FAB in a Chilean population; (3) assess the sociodemographic influence in the performance of the FAB in a sample of healthy controls (HC); and (4) develop normative data for this healthy group. Methods: A HC (n=344) and a group of patients with dementia (n=156) were assessed with the Chilean version of FAB. Results: FAB showed good internal consistency (Cronbach's alpha=0.79) and acceptable validity based on the relationship with other variables. Factor analysis showed the unidimensionality of the instrument. Significant differences were found in the total FAB value between the HC and dementia groups. With the matched sample, the established cutoff point was 13.5, showing a sensitivity of 80.8% and a specificity of 90.4%. Regression analysis showed that education and age significantly predicted FAB performance in the healthy group. Finally, normative data are provided. Conclusions: This study shows that FAB is a useful tool to discriminate between healthy people and people with dementia. However, further studies are needed to explore the capacity of the instrument to characterize the dysexecutive syndrome in people with dementia in the Chilean population.</jats:p>
Scopus© Citations 2 11
Some of the metrics are blocked by your
consent settings
Multidimensional Clinical Assessment in Frontotemporal Dementia and Its Spectrum in Latin America and the Caribbean: A Narrative Review and a Glance at Future Challenges
(2022)
Fernando Henríquez
;
Victoria Cabello
;
Sandra Baez
;
Leonardo Cruz de Souza
;
Patricia Lillo
<jats:p>Frontotemporal dementia (FTD) is the third most common form of dementia across all age groups and is a leading cause of early-onset dementia. The Frontotemporal dementia (FTD) includes a spectrum of diseases that are classified according to their clinical presentation and patterns of neurodegeneration. There are two main types of FTD: behavioral FTD variant (bvFTD), characterized by a deterioration in social function, behavior, and personality; and primary progressive aphasias (PPA), characterized by a deficit in language skills. There are other types of FTD-related disorders that present motor impairment and/or parkinsonism, including FTD with motor neuron disease (FTD-MND), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). The FTD and its associated disorders present great clinical heterogeneity. The diagnosis of FTD is based on the identification through clinical assessments of a specific clinical phenotype of impairments in different domains, complemented by an evaluation through instruments, i.e., tests and questionnaires, validated for the population under study, thus, achieving timely detection and treatment. While the prevalence of dementia in Latin America and the Caribbean (LAC) is increasing rapidly, there is still a lack of standardized instruments and consensus for FTD diagnosis. In this context, it is important to review the published tests and questionnaires adapted and/or validated in LAC for the assessment of cognition, behavior, functionality, and gait in FTD and its spectrum. Therefore, our paper has three main goals. First, to present a narrative review of the main tests and questionnaires published in LAC for the assessment of FTD and its spectrum in six dimensions: (i) Cognitive screening; (ii) Neuropsychological assessment divided by cognitive domain; (iii) Gait assessment; (iv) Behavioral and neuropsychiatric symptoms; (v) Functional assessment; and (vi) Global Rating Scale. Second, to propose a multidimensional clinical assessment of FTD in LAC identifying the main gaps. Lastly, it is proposed to create a LAC consortium that will discuss strategies to address the current challenges in the field.</jats:p>
1 4Scopus© Citations 18
Some of the metrics are blocked by your
consent settings
GERO Cohort Protocol, Chile, 2017–2022: Community-based Cohort of Functional Decline in Subjective Cognitive Complaint elderly
(2020)
Andrea Slachevsky
;
Pedro Zitko
;
David Martínez-Pernía
;
Gonzalo Forno
;
Felipe A. Court
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>With the global population aging and life expectancy increasing, dementia has turned a priority in the health care system. In Chile, dementia is one of the most important causes of disability in the elderly and the most rapidly growing cause of death in the last 20 years. Cognitive complaint is considered a predictor for cognitive and functional decline, incident mild cognitive impairment, and incident dementia. The GERO cohort is the Chilean core clinical project of the Geroscience Center for Brain Health and Metabolism (GERO). The objective of the GERO cohort is to analyze the rate of functional decline and progression to clinical dementia and their associated risk factors in a community-dwelling elderly with subjective cognitive complaint, through a population-based study. We also aim to undertake clinical research on brain ageing and dementia disorders, to create data and biobanks with the appropriate infrastructure to conduct other studies and facilitate to the national and international scientific community access to the data and samples for research.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The GERO cohort aims the recruitment of 300 elderly subjects (> 70 years) from Santiago (Chile), following them up for at least 3 years. Eligible people are adults not diagnosed with dementia with subjective cognitive complaint, which are reported either by the participant, a proxy or both. Participants are identified through a household census. The protocol for evaluation is based on a multidimensional approach including socio-demographic, biomedical, psychosocial, neuropsychological, neuropsychiatric and motor assessments. Neuroimaging, blood and stool samples are also obtained. This multidimensional evaluation is carried out in a baseline and 2 follow-ups assessments, at 18 and 36 months. In addition, in months 6, 12, 24, and 30, a telephone interview is performed in order to keep contact with the participants and to assess general well-being.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>Our work will allow us to determine multidimensional risks factors associated with functional decline and conversion to dementia in elderly with subjective cognitive complain. The aim of our GERO group is to establish the capacity to foster cutting edge and multidisciplinary research on aging in Chile including basic and clinical research.</jats:p></jats:sec><jats:sec><jats:title>Trial registration</jats:title><jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04265482">NCT04265482</jats:ext-link>in ClinicalTrials.gov. Registration Date: February 11, 2020. Retrospectively Registered.</jats:p></jats:sec>
Scopus© Citations 13 2
Some of the metrics are blocked by your
consent settings
Using game authoring platforms to develop screen-based simulated functional assessments in persons with executive dysfunction following traumatic brain injury
(2017)
David Martínez-Pernía
;
Javier Núñez-Huasaf
;
Ángel del Blanco
;
Amparo Ruiz-Tagle
;
Juan Velásquez
4Scopus© Citations 22

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results